Xponance Inc. Has $237,000 Stock Holdings in Arcellx, Inc. (NASDAQ:ACLX)

Xponance Inc. boosted its position in Arcellx, Inc. (NASDAQ:ACLX) by 8.6% during the 4th quarter, Holdings Channel reports. The fund owned 3,088 shares of the company’s stock after buying an additional 244 shares during the period. Xponance Inc.’s holdings in Arcellx were worth $237,000 as of its most recent SEC filing.

Other hedge funds have also recently added to or reduced their stakes in the company. KBC Group NV grew its position in Arcellx by 37.3% in the 4th quarter. KBC Group NV now owns 1,388 shares of the company’s stock valued at $106,000 after purchasing an additional 377 shares during the period. Quarry LP acquired a new position in shares of Arcellx during the third quarter valued at about $125,000. Quest Partners LLC increased its position in shares of Arcellx by 210.1% during the third quarter. Quest Partners LLC now owns 1,532 shares of the company’s stock worth $128,000 after acquiring an additional 1,038 shares in the last quarter. Avanza Fonder AB acquired a new stake in shares of Arcellx in the 4th quarter worth about $184,000. Finally, Glenmede Trust Co. NA bought a new position in Arcellx in the 3rd quarter valued at about $302,000. Institutional investors and hedge funds own 96.03% of the company’s stock.

Insider Transactions at Arcellx

In related news, insider Christopher Heery sold 3,301 shares of the firm’s stock in a transaction that occurred on Friday, January 3rd. The shares were sold at an average price of $79.55, for a total value of $262,594.55. Following the completion of the transaction, the insider now directly owns 35,517 shares of the company’s stock, valued at approximately $2,825,377.35. This trade represents a 8.50 % decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, Director Kavita Patel sold 1,500 shares of Arcellx stock in a transaction that occurred on Tuesday, February 4th. The shares were sold at an average price of $64.57, for a total transaction of $96,855.00. The disclosure for this sale can be found here. Insiders sold 64,370 shares of company stock worth $4,181,646 over the last quarter. Corporate insiders own 6.24% of the company’s stock.

Arcellx Trading Down 0.8 %

Arcellx stock opened at $67.96 on Friday. The company has a market cap of $3.73 billion, a price-to-earnings ratio of -95.72 and a beta of 0.32. The business’s 50 day simple moving average is $66.93 and its 200 day simple moving average is $77.70. Arcellx, Inc. has a 12 month low of $47.88 and a 12 month high of $107.37.

Arcellx (NASDAQ:ACLX) last announced its quarterly earnings data on Thursday, February 27th. The company reported ($0.87) earnings per share for the quarter, missing the consensus estimate of ($0.63) by ($0.24). Arcellx had a negative return on equity of 8.28% and a negative net margin of 25.94%. The firm had revenue of $15.27 million during the quarter, compared to analysts’ expectations of $27.42 million. As a group, equities research analysts forecast that Arcellx, Inc. will post -1.58 earnings per share for the current fiscal year.

Analyst Upgrades and Downgrades

Several brokerages have recently commented on ACLX. HC Wainwright reissued a “buy” rating and issued a $115.00 price objective on shares of Arcellx in a research note on Tuesday, December 10th. Needham & Company LLC restated a “buy” rating and set a $105.00 price objective on shares of Arcellx in a research note on Monday, December 9th. UBS Group upped their target price on shares of Arcellx from $106.00 to $114.00 and gave the stock a “buy” rating in a research note on Tuesday, December 10th. Finally, Barclays upgraded shares of Arcellx to a “strong-buy” rating in a report on Friday, November 29th. Thirteen investment analysts have rated the stock with a buy rating and two have issued a strong buy rating to the company. According to MarketBeat.com, the company presently has a consensus rating of “Buy” and a consensus target price of $108.46.

About Arcellx

Arcellx, Inc, together with its subsidiary, engages in the development of various immunotherapies for patients with cancer and other incurable diseases in the United States. The company’s lead ddCAR product candidate is anitocabtagene autoleucel, which is in phase 2 clinical trial for the treatment of patients with relapsed or refractory multiple myeloma (rrMM).